GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Operating Margin %

OncoSec Medical (FRA:ONMA) Operating Margin % : 0.00% (As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. OncoSec Medical's Operating Income for the three months ended in Jan. 2023 was €-7.11 Mil. OncoSec Medical's Revenue for the three months ended in Jan. 2023 was €0.00 Mil. Therefore, OncoSec Medical's Operating Margin % for the quarter that ended in Jan. 2023 was 0.00%.

The historical rank and industry rank for OncoSec Medical's Operating Margin % or its related term are showing as below:


FRA:ONMA's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -157.4
* Ranked among companies with meaningful Operating Margin % only.

OncoSec Medical's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

OncoSec Medical's Operating Income for the three months ended in Jan. 2023 was €-7.11 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2023 was €-31.36 Mil.


OncoSec Medical Operating Margin % Historical Data

The historical data trend for OncoSec Medical's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Operating Margin % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Operating Margin %

For the Biotechnology subindustry, OncoSec Medical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Operating Margin % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Operating Margin % falls into.



OncoSec Medical Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

OncoSec Medical's Operating Margin % for the fiscal year that ended in Jul. 2022 is calculated as

Operating Margin %=Operating Income (A: Jul. 2022 ) / Revenue (A: Jul. 2022 )
=-36.383 / 0
= %

OncoSec Medical's Operating Margin % for the quarter that ended in Jan. 2023 is calculated as

Operating Margin %=Operating Income (Q: Jan. 2023 ) / Revenue (Q: Jan. 2023 )
=-7.112 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (FRA:ONMA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


OncoSec Medical Operating Margin % Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines